TMEM30B

Across TCGA pan-cancer cohorts, TMEM30B mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TMEM30B data layer compared with 19 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher TMEM30B mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated TMEM30B expression acts as an unfavorable survival marker, although some lineages such as HNSC and PDAC show a favorable association.

LUAD, HNSC, and PDAC are the cancer types where TMEM30B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Quartile	II,III,IV	0.335	0.894	.004	8	view →
HNSC	DFS	Quartile	All	0.927	0.633	.010	6	view →
PDAC	DFS	Quartile	All	0.531	0.322	.019	6	view →
LSCC	DFS	Quartile	II,III,IV	0.886	1.000	.029	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TMEM30B–LUAD (OS)

Open the LUAD breakdown →